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Abstract
Objectives. This study aimed to estimate the prevalence of US-detected tenosynovitis in RA patients in
clinical remission and to explore its clinical correlates.
Methods. A total of 427 RA patients in clinical remission were consecutively enrolled from 25 Italian
rheumatology centres. Tenosynovitis and synovitis were scored by US grey scale (GS) and power
Doppler (PD) semi-quantitative scoring systems at wrist and hand joints. Complete clinical assessment
was performed by rheumatologists blinded to the US results. A flare questionnaire was used to assess
unstable remission (primary outcome), HAQ for functional disability and radiographic erosions for damage
(secondary outcomes). Cross-sectional relationships between the presence of each US finding and
outcome variables are presented as odds ratios (ORs) and 95% CIs, both crude and adjusted for pre-
specified confounders.
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Results. The prevalence of tenosynovitis in clinical remission was 52.5% (95% CI 0.48, 0.57) for GS and
22.7% (95% CI 0.19, 0.27) for PD, while the prevalence of synovitis was 71.6% (95% CI 0.67, 0.76) for GS
and 42% (95% CI 0.37, 0.47) for PD. Among clinical correlates, PD tenosynovitis associated with lower
remission duration and morning stiffness while PD synovitis did not. Only PD tenosynovitis showed a
significant association with the flare questionnaire [OR 1.95 (95% CI 1.17, 3.26)]. No cross-sectional
associations were found with the HAQ. The presence of radiographic erosions associated with GS and
PD synovitis but not with tenosynovitis.
Conclusions. US-detected tenosynovitis is a frequent finding in RA patients in clinical remission and
associates with unstable remission.
Key words: rheumatoid arthritis, remission, tenosynovitis, ultrasound, flare
Rheumatology key messages
. Ultrasound-detected tenosynovitis is a frequent finding in RA in clinical remission.
. Compared with intra-articular synovitis, active tenosynovitis is more associated with RA patients reporting
unstable remission.
. The ultrasonographic assessment of tendon sheaths may help in subsetting RA patients in clinical remission.
Introduction
Remission is the current target of treatment in patients
with RA [1]. Nevertheless, the definition of remission in
RA is still a matter of debate. Ideally, remission may be
defined as a condition characterized by the absence of
clinically detectable disease activity, the arrest of radio-
graphic progression and the normalization or maximal im-
provement of physical function [2]. However, the
assessment of remission is frequently a challenge in clin-
ical practice. Subclinical disease activity may be present
even if a patient fits the proposed definitions of clinical
remission, leading to joint damage progression [36] and
disease flare [6, 7].
Imaging, in particular musculoskeletal ultrasonography
(MSUS), is useful in overcoming the limitations of clinical
measures of disease activity [3, 4, 8]. Even in the absence
of clinically detectable joint swelling, imaging can reveal
synovial effusion and synovial hypertrophy using grey-
scale (GS) mode and synovial active inflammation using
the power Doppler (PD) technique [5]. Moreover, MSUS is
reliable and sensitive to change and can provide diagnos-
tic and prognostic data in terms of risk of flare, disability
and anatomical damage progression at different stages of
RA [7, 911]. For these reasons, several MSUS studies
performed in RA patients in clinical remission have
focused on assessing subclinical joint synovitis to identify
patients with subclinical disease activity. In several stu-
dies, the majority of patients in clinical remission
showed persistent GS (5090%) and PD synovitis
(4060%) [10, 12]. Although GS synovitis has been re-
ported to be poorly associated with clinical and radio-
logical outcomes [4, 13], PD occurring in RA patients in
clinical remission leads to a clinically meaningful
increased risk of flare over time, with odds ratios (ORs)
ranging from 3 to 10, suggesting that PD may help in
identifying patients with subclinical disease [9, 14].
Furthermore, the association of PD synovitis with future
occurrence of disability and structural damage strength-
ens the plausibility of this association and the validity of
such a measure [15]. However, it should be taken into
account that RA inflammation may be located not only
within the joints, but also at the level of the periarticular
synovial structures such as tendon sheaths. Indeed, as
well as synovitis, tenosynovitis is a typical manifestation
of RA, which associates with pain and erosive evolution in
early disease [11, 16], tendon ruptures [16, 17] and dis-
ability. In spite of this, very few data are available on both
its prevalence in RA patients and its prognostic signifi-
cance in the subpopulation of RA patients in clinical re-
mission [18, 19]. This lack of information might be partially
due to the difficulty in differentiating between articular and
tendon swelling by clinical examination. In this context,
MSUS may be the best imaging method to characterize
tenosynovitis and to evaluate its frequency and prognostic
significance in RA patients in clinical remission.
On this basis, the MSUS Study Group of the Italian
Society for Rheumatology (SIR) prioritized its research
activities on assessment of the prevalence and clinical
significance of MSUS-detected tenosynovitis in RA pa-
tients in clinical remission, launching a multicentre study,
the Sonographic Tenosynovitis Assessment in
Rheumatoid Arthritis Patients in Remission (STARTER)
study. The objective of this study was to determine the
prevalence of US tenosynovitis (and synovitis) at baseline
in RA patients in clinical remission and its association with
unstable remission, function and damage.
Methods
Patient and study design
This is a cross-sectional analysis of the STARTER study,
which is a multicentre observational study promoted by
the MSUS Study Group of the SIR and includes 25 Italian
rheumatology centres, recruited on voluntary basis. In this
context, consecutive patients classified as RA according
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to the 1987 ACR criteria or 2010 ACR/EULAR criteria and
in clinical remission were recruited between October 2013
and June 2014. Patients were considered eligible if they
met at least one of the following remission criteria at the
screening visit: 28-joint DAS (DAS28) < 2.6 [20], Simplified
Disease Activity Index (SDAI) 43.3 [21], Clinical Disease
Activity Index (CDAI) 42.8 [22], ACR/EULAR Boolean def-
inition [21], absence of swollen/tender joints on 28 joints
[23] or remission based on clinical evaluation of an expert
rheumatologist [3]. All patients underwent a complete clin-
ical assessment and an MSUS examination.
The STARTER study was approved by the local ethics
committee for each of the participating sites. Written in-
formed consent was obtained from all participants. This
analysis did not require separate ethical approval.
Clinical assessment
For each patient, complete demographic (age, sex, type
of occupational activity, smoking habit), anamnestic (date
of RA onset and diagnosis, disease and remission dur-
ation, co-morbidities, previous and current therapy for
RA) and clinimetric [weight and height, the Italian version
of the HAQ [24], flare questionnaire (FQ) [25, 26], duration
of morning stiffness, visual analogue scale (VAS) for joint
pain, physician global assessment, patient global assess-
ment and global health] data were collected; laboratory
data such as ESR, CRP, RF and ACPA positivity and
titres were recorded. In addition, a standard 28-joint
count was performed. Plain radiographs of the hands,
wrists and feet were also collected. The clinical assess-
ment was performed by a clinical rheumatologist at each
centre who was blinded to the US results.
Outcome measures
Unstable remission disease was set as the primary out-
come of the analysis and defined according to the FQ
value over its median value (3) in our study sample.
Secondary outcomes included functional disability, eval-
uated by the Italian version of the HAQ score >0.5 [27],
and bone damage, defined as the presence of typical
bone erosions at baseline radiographs as reported by
the investigator.
Ultrasonographic assessment
All ultrasonographers participating in the study were ex-
perts in MSUS and were selected on the basis of an inter-
and intra-observer reliability exercise against a reference
standard (AI) on static images using an e-learning plat-
form. Only ultrasonographers for whom the results of the
reliability assessment were from good to excellent
(weighted k 50.7) [28] were allowed to participate in the
study. In addition, the equipment level available at the
different sites was assessed and only high-level US ma-
chines (MyLab 70XVG, MyLab Twice, Logiq9, LogiqE9)
with high-frequency linear probes (1418 MHz) were
allowed. High-level US machines were provided by
Esaote (Genoa, Italy) to those investigators who passed
the reliability exercise test but who did not have an ad-
equate US machine at their site. MSUS examination was
performed according to the EULAR guidelines [29]. In
each rheumatology unit, the MSUS evaluations were per-
formed by a single rheumatologist expert in MSUS who
was blinded to the clinical data.
The MSUS tendon scanning protocol included multipla-
nar longitudinal and transverse scanning of flexor and ex-
tensor tendon sheaths of the wrist and fingers bilaterally
and longitudinal scanning of the dorsal aspect of the wrist
(radiocarpal and mid-carpal joint) with joints in a neutral
position. Specifically, extensor tendons of the wrist were
examined from the Lister’s tubercle to the metacarpal
bones. Flexor tendons at the wrist were examined from
the proximal edge of the carpal tunnel to the palm of the
hand, while the flexor radialis carpi tendon was examined
in its pre-insertional and insertional tract where the syn-
ovial sheath is present. Flexor digitorum tendons and
flexor pollicis longus tendon were examined from the
palm of the hand to the distal phalanx. The MSUS joint
scanning protocol included multiplanar longitudinal scan-
ning of the dorsal aspects of the MCP joints bilaterally and
longitudinal scanning of the palmar aspects of the PIP
joints bilaterally. Tenosynovitis, joint effusion and synovial
hypertrophy were identified according to OMERACT def-
initions [30]. In particular, tenosynovitis was defined as the
presence of hypoechoic or anechoic thickened tissue with
or without fluid within the tendon sheath, which is seen in
two perpendicular planes and which may exhibit PD signal
[30].
Synovial and tenosynovial PD were evaluated by select-
ing a region of interest that included the bony margins,
joint space and a variable view of surrounding tissues,
using abundant US gel to avoid pressure on the tissues.
US machine settings were adjusted to the lowest permis-
sible pulse repetition frequency (500750 Hz) to maximize
sensitivity. Doppler frequency was set high (7.514.3 MHz)
to optimize the detection of flow at the level of small joints
and superficial tissues. Colour gain was set just below the
level that caused the appearance of noise artefacts. In all
findings, flow was confirmed in two perpendicular planes.
GS tenosynovitis was semi-quantitatively scored from 0
to 3 (0 = normal; 1 = mild; 2 = moderate; 3 = marked); PD
tenosynovitis signal was also assessed using a 03
semi-quantitative score (0 = absence or minimal flow;
1 = mild: single vessel signal; 2 = moderate: confluent ves-
sels; 3 = marked: vessel signals in >50% of the tenosyno-
vial tissue) [31]. US-detected synovitis and joint effusion
were scored together according to a 03 semi-quantita-
tive simplified score [32] and PD synovitis was also semi-
quantitatively graded from 0 to 3, as previously reported
(Fig. 1) [33]. At the end of each US exam, total scores for
GS tenosynovitis, PD tenosynovitis, GS synovitis and PD
synovitis were calculated by summing the scores de-
tected at different sites. We defined GS tenosynovitis re-
mission as a total score in GS tenosynovitis of 0, PD
tenosynovitis remission as a total score in PD tenosyno-
vitis of 0, GS synovitis remission as a total score in GS
synovitis of 0 and PD synovitis remission as a total score
in PD synovitis of 0. Representative scan images of each
MSUS exam were recorded.
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FIG. 1 US scoring system
Scoring of tenosynovitis (panel A: finger flexor at the MCP joint) and synovitis (panel B: dorsal aspect of the MCP joint).
Images provided by Georgios Filippou.
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Statistical analysis
The prevalence of tenosynovitis was evaluated on the
basis of different remission criteria and presented with
its corresponding exact 95% CI. The association between
demographic, clinical, serological and treatment variables
was explored by the chi-square or Wilcoxon test based on
the variable type and distribution and correlation using
Spearman’s r coefficient.
The cross-sectional relationship between the presence
of GS tenosynovitis/synovitis, PD tenosynovitis/synovitis
and outcome variables (FQ positivity, HAQ score and ero-
sive damage) were evaluated by logistic models and pre-
sented as ORs and 95% CIs, both crude and adjusted for
pre-specified confounders, coded as follows: age (quar-
tiles: 1847, 4856, 5765, 566 years), sex (categorical),
disease duration (quartiles: 03.99, 47.49, 7.513.49,
513.5 years), remission duration (07.9, 811.9, 1223.9,
524 months), musculoskeletal co-morbidities (dichotom-
ous), RF (dichotomous), ACPA (dichotomous), concurrent
DMARDs (dichotomous), biologics (dichotomous),
NSAIDs (dichotomous) and systemic and locally injected
glucocorticoids (dichotomous) [14, 18, 3437].
Study data were collected and managed using Research
Electronic Data Capture. Research Electronic Data Capture
is a free, secure, Web-based application designed to sup-
port data capture for research studies, providing an intuitive
interface for validated data entry, audit trails for tracking
data manipulation and export procedures, automated
export procedures for seamless and anonymous data
downloads to common statistical packages and proced-
ures for importing data from external sources [38].
Analyses were performed using STATA software (2009, re-
lease 11; StataCorp, College Station, TX, USA).
Results
Participants and descriptive data
A total of 427 patients were included in the analysis: com-
plete history, clinical, clinimetric and serological charac-
teristics of the study population are described in Table 1.
Median disease duration was 7.32 years [interquartile
range (IQR) 3.813.48] and median remission duration
was 12 months (IQR 824). A total of 283 patients
(68.52%) were in DAS28 remission, 281 patients
(65.81%) were in CDAI remission, 288 patients (67.76%)
were in SDAI remission and 234 patients (54.8%) fulfilled
the ACR/EULAR remission criteria.
Prevalence of tenosynovitis in clinical remission
GS tenosynovitis remission was present in 203 patients
[47.5% (95% CI 0.43, 0.52)] and PD tenosynovitis remis-
sion was present in 330 patients [77.3% (95% CI 0.73,
0.81)], while GS synovitis remission was present in 121
patients [28.4% (95% CI 0.24, 0.33)] and PD synovitis re-
mission in 247 patients [57.9% (95% CI 0.53, 0.63)]. A
total of 78% of patients in DAS28 remission were in PD
tenosynovitis remission and 49% were in GS tenosyno-
vitis remission (Table 2). No significant differences were
found in the proportion of patients in remission according
to MSUS variables within other clinical remission criteria
(CDAI, SDAI and ACR/EULAR Boolean definition). The de-
tails of the distribution of MSUS variables are reported in
supplementary Table S1 and Fig. S1, available at
Rheumatology Online.
Regarding MSUS synovitis, 58% of patients in DAS28
remission and 62% of patients in remission as per the
ACR/EULAR Boolean definition were in PD synovitis re-
mission; 29% of patients in DAS28 remission and 32% of
patients in remission as per the ACR/EULAR definition
were in GS synovitis remission (Table 2). Concerning GS
tenosynovitis/PD tenosynovitis, the involvement of the
sixth extensor tendon compartment of the wrist bilaterally
was most commonly observed, while GS synovitis/PD
synovitis was mostly found at wrist and second and
third MCP joints bilaterally, with a predominance of right
side involvement. Other common sites of GS
TABLE 1 Summary of patients’ characteristics (n = 427)
Sex, male, n (%) 113 (26.46)
Age, mean (S.D.), years 56.61 (13.39)
Occupation, n (%)
No occupation 165 (38.64)
Manual work 123 (28.81)
Not manual work 139 (32.55)
BMI, mean (S.D.) 24.55 (4.09)
Smoke, n (%)
Never 239 (56.10)
Ex-smokers 112 (26.29)
Smokers 75 (17.61)
Disease duration, years, median (IQR) 7.32 (3.813.48)
Remission duration, months, median (IQR) 12 (824)
RA extra-articular manifestation, n (%) 122 (28.57)
Musculoskeletal co-morbidities, n (%)
FM 14 (3.28)
OA 90 (21.08)
Microcrystalline arthropathy 3 (0.70)
Ongoing DMARD therapy, n (%)a 322 (75.41)
Ongoing biologic therapy, n (%)b 183 (42.86)
Ongoing corticosteroid therapy, n (%) 187 (43.79)
Steroid infiltration in the last month, n (%) 7 (1.64)
NSAIDs, n (%)
On-demand 237 (55.5)
Continuous 6 (1.41)
RF, n (%)
Negative 139 (32.63)
Positive 287 (67.37)
ACPA, n (%)
Negative 142 (33.41)
Positive 283 (66.58)
Erosive RA, n (%) 232 (54.59)
ESR, mean (S.D.) 15.66 (13.54)
Negative CRP, n (%)c 362 (85.18)
Flare questionnaire score, median (IQR) 3 (015)
HAQ, median (IQR) 0.125 (00.375)
Tender joints, median (IQR) 0 (01)
Swollen joints, median (IQR) 0 (00)
DAS28, mean (S.D.) 2.24 (0.85)
Morning stiffness, minutes, mean (S.D.) 7.42 (14.68)
CDAI, mean (S.D.) 2.60 (2.98)
SDAI, mean (S.D.) 2.96 (3.67)
aMTX, LEF, SSZ, HCQ, ciclosporin and gold salts. bTNF-a
inhibitors, rituximab, abatacept and tocilizumab. cCRP under
site-specific cut-off.
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tenosynovitis/PD tenosynovitis detection were the fourth
extensor tendon compartment of the wrist bilaterally, the
flexor tendons of the second finger bilaterally and the
flexor tendons of the third and fourth fingers of the right
hand (supplementary Tables S2 and S3, available at
Rheumatology Online).
Clinical correlates of US tenosynovitis and US
synovitis
As shown in Table 3, shorter remission duration and
higher swollen joint count were significantly and positively
associated with PD and GS tenosynovitis. Higher BMI, RF
TABLE 2 Prevalence of US remission in patients in clinical remission
MSUS remission DAS28 remission CDAI remission SDAI remission
ACR/EULAR
remission
Clinical
remissiona
PD tenosynovitis remission 0.78 (0.73, 0.83) 0.79 (0.73, 0.83) 0.78 (0.73, 0.83) 0.79 (0.73, 0.84) 0.81 (0.76, 0.86)
GS tenosynovitis remission 0.49 (0.43, 0.55) 0.51 (0.45, 0.57) 0.5 (0.44, 0.56) 0.51 (0.44, 0.57) 0.55 (0.48, 0.61)
PD synovitis remission 0.58 (0.52, 0.63) 0.62 (0.56, 0.68) 0.61 (0.55, 0.67) 0.62 (0.55, 0.68) 0.65 (0.59, 0.71)
GS synovitis remission 0.29 (0.24, 0.35) 0.33 (0.27, 0.39) 0.32 (0.26, 0.37) 0.32 (0.26, 0.38) 0.34 (0.29, 0.41)
Values are presented as prevalence (95% CI). aClinical remission: absence of swollen/tender joints on 28 joints.
TABLE 3 Clinical correlates of MSUS tenosynovitis
Variable
Power Doppler Grey scale
Negative
(n = 330)
Positive
(n = 97) P-value
Negative
(n = 203)
Positive
(n = 224) P-value
Sex, male, n (%) 82 (24.85) 31 (31.96) 0.163 56 (27.59) 57 (25.45) 0.617
Age, mean (S.D.), years 56.37 (13.76) 57.4 (12.1) 0.508 54.93 (14.05) 58.13 (12.61) 0.014
BMI, mean (S.D.) 24.27 (3.99) 25.51 (4.3) 0.013 24.23 (4.17) 24.85 (4) 0.142
Smoke, n (%)
Never 188 (56.97) 51 (53.12) 0.459 110 (54.46) 129 (57.59) 0.556
Ex-smokers 88 (26.67) 24 (25) 58 (28.71) 54 (24.11)
Smokers 54 (16.36) 21 (21.88) 34 (16.83) 41 (18.30)
Occupation, n (%)
No occupation 128 (38.79) 37 (38.14) 0.967 75 (36.95) 90 (40.18) 0.258
Manual work 94 (28.48) 29 (29.90) 54 (26.60) 69 (30.80)
Not manual work 108 (32.73) 31 (31.96) 74 (36.45) 65 (29.02)
Disease duration, median (IQR), years 7.55 (3.9113.2) 6.39 (3.5813.86) 0.683 7.06 (3.7913.2) 7.66 (3.9113.79) 0.437
Remission duration >12 months, n (%) 168 (50.91) 30 (30.93) 0.001 107 (52.71) 91 (40.63) 0.015
Ongoing DMARDS therapy, n (%)a 246 (74.55) 76 (78.35) 0.444 152 (74.88) 170 (75.89) 0.808
Ongoing biologic therapy, n (%)b 140 (42.42) 43 (44.33) 0.739 85 (41.87) 98 (43.75) 0.695
Ongoing corticosteroid therapy, n (%) 141 (42.73) 46 (47.42) 0.413 84 (41.38) 103 (45.98) 0.338
Steroid infiltration in the last month, n (%) 5 (1.52) 2 (2.06) 0.712 5 (2.48) 2 (0.89) 0.2
NSAIDs, n (%)
On demand 176 (53.33) 61 (62.89) 0.248 110 (54.19) 127 (56.7) 0.645
Continuous 5 (1.52) 1 (1.03) 2 (0.99) 4 (1.79)
RF, n (%)
Negative 125 (37.99) 14 (14.43) <0.001 72 (35.64) 67 (29.91) 0.164
Negative, but positive in the past 38 (11.55) 7 (7.22) 16 (7.92) 29 (12.95)
Positive 166 (50.46) 76 (78.35) 114 (56.44) 128 (57.14)
ACPA, n (%)
Negative 122 (37.20) 20 (20.62) 0.004 67 (33.17) 75 (33.63) 0.755
Negative, but positive in the past 31 (9.45) 7 (7.22) 16 (7.92) 22 (9.87)
Positive 175 (53.35) 70 (72.16) 119 (58.91) 126 (56.50)
Erosive RA, n (%) 176 (53.66) 56 (57.73) 0.479 105 (51.98) 127 (56.95) 0.304
ESR, mean (S.D.) 15.77 (14.05) 15.29 (11.79) 0.871 16.92 (15.31) 14.53 (11.65) 0.192
Negative CRP, n (%)c 284 (86.59) 78 (80.41) 0.133 171 (85.07) 191 (85.27) 0.955
Flare questionnaire score, median (IQR) 2 (014) 7 (017) 0.017 2 (019) 3 (013) 0.717
HAQ, median (IQR) 0.125 (00.375) 0.125 (00.5) 0.167 0.125 (00.375) 0.125 (00.375) 0.473
Tender joints, median (IQR) 0 (01) 0 (01) 0.189 0 (00) 0 (01) 0.058
Swollen joints, median (IQR) 0 (00) 0 (01) 0.017 0 (00) 0 (01) 0.003
DAS28, mean (S.D.) 2.21 (0.87) 2.33 (0.78) 0.23 2.21 (0.89) 2.27 (0.82) 0.54
CDAI, mean (S.D.) 2.49 (2.87) 3 (3.29) 0.089 2.35 (3.12) 2.83 (0.83) 0.002
SDAI, mean (S.D.) 2.89 (3.77) 3.22 (3.32) 0.163 2.63 (3.3) 3.26 (3.96) 0.003
aMTX, LEF, SSZ, HCQ, ciclosporin and gold salts. bTNF-a inhibitors, rituximab, abatacept and tocilizumab. cCRP under cut-off.
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positivity, ACPA positivity and FQ score were significantly
and positively associated with PD tenosynovitis, while a
significant positive association was found between GS
tenosynovitis and older age, higher CDAI and higher
SDAI scores.
Similar results were found also for PD and GS synovitis,
which were significantly and positively associated with
corticosteroid therapy, RF and ACPA positivity, erosive
RA, higher swollen joint count and higher CDAI and
SDAI scores (Table 4). Also, GS synovitis was significantly
and positively associated with male sex, older age and
shorter remission duration. Analysing clinical correlates
of MSUS variables as continuous variables, morning stiff-
ness was significantly associated with PD tenosynovitis (r
= 0.29, P< 0.05), while PD synovitis did not (r =0.01,
P> 0.05).
Cross-sectional associations of US tenosynovitis and
US synovitis with FQ, function and damage
Exploring associations of MSUS variables with potentially
relevant outcome, tenosynovitis associated with FQ
score, with a 2-fold higher probability of having a higher
score in patients with the presence of PD tenosynovitis,
even after adjustment for pre-specified confounders. No
significant associations were found for GS tenosynovitis
and synovitis, both PD and GS (Table 5).
Neither tenosynovitis nor synovitis US variables showed
any significant association with the presence of at least
mild functional disability, as measured by the HAQ. Similar
results were obtained restricting the sample to short re-
mission duration (<12 months) and to active workers. The
presence of radiographic erosions showed a significant
association with synovial MSUS variables, both GS and
PD synovitis, particularly GS synovitis, which showed a
2-fold increase of the probability of erosive disease, still
significant even after adjusting for the full set of
confounders.
Discussion
This multicentre study was designed to evaluate the
prevalence of US-detected tenosynovitis in RA patients
in clinical remission and to evaluate its clinical correlates
and its association with the risk of flare, worsening of
functional disability and damage. Although tenosynovitis
is recognized as a typical extra-articular RA manifestation,
few data are present in the literature on its real prevalence,
and the published data on its prognostic significance
in RA patients in clinical remission are even more limited
[39, 40].
The diagnostic and prognostic value of US-detected
articular synovitis have been demonstrated in the last
few years. In particular, in the subpopulation of RA pa-
tients in clinical remission, great effort was made in defin-
ing the prognostic significance of ongoing PD-positive
synovitis, leading to the conclusion that the definition of
remission status should be reserved for patients who are
both in a state of clinical remission defined by clinimetric
indexes and show the absence of synovitis on imaging
studies [8]. In this regard, the STARTER study contributes
in better defining imaging remission, studying for the first
time systematically US-detected tenosynovitis of the hand
and wrist joints of RA patients in clinical remission.
The results of these analyses confirm the potential role
of US tenosynovial-targeted assessment in RA patients in
clinical remission. To the best of our knowledge,
STARTER is one of the largest cohorts of RA patients in
clinical remission assessed by MSUS ever reported,
including 427 patients. In our study sample we found a
significant proportion of patients with the presence of GS
tenosynovitis (52.5%) and PD tenosynovitis (22.7%), while
the prevalence of GS synovitis (71.6%) and PD synovitis
(42%) were in agreement with previous studies [10, 12].
The lower prevalence of tenosynovitis makes this US
feature a possibly more specific tool to identify subclinical
inflammation compared with US synovitis. Indeed, al-
though PD synovitis is very sensitive in predicting short-
term flare, it has a low positive predictive value: a large
number of RA patients in clinical remission with PD syno-
vitis do not relapse, mainly in long-standing disease [36].
The results of our study suggest that PD tenosynovitis
could be more specific than PD synovitis in identifying
patients with ongoing active disease and unstable clinical
remission, as that was the only US variable significantly
associated with FQ.
Furthermore, the combined synovial and tenosynovial
US assessment could be useful to stratify patients ac-
cording to the type and site of subclinical inflammation.
In fact, in our population, PD tenosynovitis significantly
correlated with two patient-reported outcomes (morning
stiffness and FQ), while synovial US findings did not: in
this context, tenosynovial involvement could explain
symptoms of the subpopulation of RA patients in clinical
remission characterized by mild relapses and unstable re-
mission but not associated with severe RA in terms of
disability or damage. On the other hand, our study con-
firms the association between erosions and the presence
of subclinical US synovitis, in both the GS and PD modes.
Among the multiple and somehow predictable associ-
ations between clinical factors and US-detected teno-
synovitis and synovitis, one of the most interesting refers
to RF and ACPA. The association between RF positivity
and clinical tenosynovitis was already evidenced in a pre-
vious study [41]. In our research we found a strong asso-
ciation between PD tenosynovitis/synovitis and RF and
ACPA positivity, while this association was lacking for
GS tenosynovitis and was even weaker for GS synovitis.
Given the well-established prognostic value of RF and
ACPA in RA patients, their association with imaging dis-
ease activity indexes suggests a link between these risk
factors and a higher risk of subclinical active disease.
The results of the present study should be interpreted in
consideration of certain limitations. In this phase the study
had a cross-sectional design, making it impossible to
draw any conclusions in terms of prognosis. Prospective
results from this study will answer this question. Patients
were consecutively—not randomly—enrolled in rheuma-
tology clinics with expertise in US, potentially introducing
a selection bias. Our cohort was apparently a
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homogeneous cohort of RA patients in clinical remission,
as it included patients in remission according to different
criteria and under different treatments. To handle this vari-
ability, an adequate sample size was planned. Given the
multisite nature of our study, there was the risk of differ-
ences in MSUS and clinical assessment leading to highly
inhomogeneous data collection. To overcome this draw-
back, ultrasonographers were trained and then selected
by an interobserver reliability exercise that showed a high
reliability rate. Also, guidelines with specific instructions
on how to perform a correct clinical assessment as
per the protocol were distributed to the clinical
rheumatologists. The residual methodological heterogen-
eity might limit the precision of the results, but it is unlikely
that it biases the results, supporting the generalizability of
the conclusions. As well as several previous imaging stu-
dies on tenosynovitis, our scanning protocol included only
hands and wrists [1618, 4244], excluding some poten-
tially relevant structures in RA, such as, for example, the
tibialis posterior tendon [45, 46]. This might decrease the
sensitivity of our US assessment, but did not threaten the
validity of our results, and clearly increased the feasibility
of a large sample study and transferability into practice.
Finally, the FQ instrument was used as an outcome
TABLE 4 Clinical correlates of MSUS synovitis
Variable
Power Doppler Grey-scale
Negative
(n = 247)
Positive
(n = 179) P-values
Negative
(n = 121)
Positive
(n = 305) P-values
Sex, male, n (%) 59 (23.89) 54 (30.17) 0.147 23 (19.01) 90 (29.51) 0.027
Age, mean (S.D.), years 56.26 (14.16) 57.23 (12.15) 0.46 54.63 (14.01) 57.87(12.9) 0.003
BMI, mean (S.D.) 24.48 (3.99) 24.67 (4.23) 0.619 24.19 (4.09) 24.71 (4.08) 0.141
Smoke, n (%)
Never 137 (55.69) 102 (56.98) 0.746 65 (54.17) 174 (57.05) 0.674
Ex-smokers 68 (27.64) 44 (24.58) 31 (25.83) 81 (26.56)
Smokers 41 (16.67) 33 (18.44) 24 (20) 50 (16.39)
Occupation, n (%)
No occupation 101 (40.89) 64 (35.75) 0.556 42 (34.71) 123 (40.33) 0.015
Manual work 69 (27.94) 53 (29.61) 27 (22.31) 95 (31.15)
Not manual work 77 (31.17) 62 (34.64) 52 (42.98) 87 (28.52)
Disease duration, median
(IQR), years
7.12 (3.6112.38) 7.88 (4.2114.99) 0.183 6.81 (3.6111.44) 7.95 (4.1013.87) 0.144
Remission duration
>12 months, n(%)
121 (48.99) 77 (43.02) 0.238 68 (56.20) 130 (42.62) 0.013
Ongoing DMARD
therapy, n (%)a
179 (72.47) 142 (79.33) 0.105 87 (71.90) 234 (76.72) 0.298
Ongoing biologic
therapy, n (%)b
115 (46.56) 68 (37.99) 0.078 51 (42.15) 132 (43.28) 0.832
Ongoing corticosteroid
therapy, n (%)
92 (37.25) 95 (53.07) 0.001 35 (28.93) 152 (49.84) <0.001
Steroid infiltration in the last
month, n (%)
2 (0.81) 5 (2.79) 0.113 2 (1.67) 5 (1.64) 0.984
NSAIDs, n (%)
On demand 132 (53.44) 104 (58.10) 0.604 71 (58.68) 165 (54.10) 0.601
Continuous 4 (1.62) 2 (1.12) 1 (0.83) 5 (1.64)
RF, n (%)
Negative 93 (37.80) 46 (25.70) 0.002 47 (38.84) 92 (30.26) 0.037
Negative, but positive
in the past
31 (12.60) 14 (7.82) 17 (14.05) 28 (9.21)
Positive 122 (49.59) 119 (66.48) 57 (47.11) 184 (60.53)
ACPA, n (%)
Negative 93 (37.80) 48 (26.97) 0.019 53 (44.17) 88 (28.95) 0.006
Negative, but positive
in the past
25 (10.16) 13 (7.30) 12 (10) 26 (8.55)
Positive 128 (52.03) 117 (65.73) 55 (45.83) 190 (62.50)
Erosive RA, n (%) 123 (50.20) 108 (60.34) 0.039 47 (39.17) 184 (60.53) <0.001
ESR, mean (S.D.) 16.1 (13.96) 15.1 (13.02) 0.527 17.11 (14.7) 15.09 (13.05) 0.15
Negative CRP, n (%)c 209 (85.31) 153 (85.47) 0.961 101 (84.87) 261 (85.57) 0.855
Flare questionnaire score,
median (IQR)
2 (015) 4 (015) 0.459 3 (012) 3 (016.5) 0.519
HAQ, median (IQR) 0.125 (00.375) 0.125 (00.375) 0.431 0.125 (00.375) 0.125 (00.375) 0.564
Tender joints, median (IQR) 0 (00) 0 (01) 0.078 0 (00) 0 (01) 0.286
Swollen joints, median (IQR) 0 (00) 0 (01) <0.001 0 (00) 0 (00) <0.001
DAS28, mean (S.D.) 2.19 (0.88) 2.3 (0.79) 0.19 2.23 (0.82) 2.24 (0.85) 0.931
CDAI, mean (S.D.) 2.18 (2.51) 3.1 (3.24) <0.001 1.87 (2.37) 2.84 (3.01) <0.001
SDAI, mean (S.D.) 2.65 (3.75) 3.29 (3.25) 0.002 2.12 (2.53) 3.23 (3.84) <0.001
aMTX, LEF, SSZ, HCQ, ciclosporin and gold salts. bTNF-a inhibitors, rituximab, abatacept and tocilizumab. cCRP under
cut-off.
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measure, although this questionnaire was still not fully
validated and there were no fully validated references for
interpreting the FQ [26]. The FQ was developed to identify
past or present RA flare, so it describes unstable remis-
sion in a setting of cross-sectional evaluation.
Despite these limitations the results of the STARTER
study indicate that US-detected tenosynovitis could be a
useful tool for rheumatologists to better define remission
as well as a subset of RA patients in clinical remission.
Tenosynovitis-targeted US evaluation should be a part of
the assessment of RA patients in clinical remission.
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